Research programme: ZW 33 - Zymeworks

Drug Profile

Research programme: ZW 33 - Zymeworks

Alternative Names: Biparatopic HER2 antibody

Latest Information Update: 22 Aug 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Zymeworks
  • Class Bispecific antibodies; Proteins
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Gastric cancer

Most Recent Events

  • 18 Aug 2016 Research programme: ZW 33 - Zymeworks receives Orphan Drug status for Ovarian cancer in USA
  • 21 Jul 2016 Zymeworks plans to submit an IND application in Canada in 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top